Clinical Trial

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this single-arm, phase II clinical trial, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC received neoadjuvant therapy with furmonertinib (oral, 80 mg once daily, stopped 1 week preoperatively) in combination with platinum-based doublet chemotherapy every 3 weeks for a total of 3 cycles. Surgery was performed 4-6 weeks after chemotherapy. The primary endpoint was objective response rate (ORR). Secondary endpoints included the pathological complete response (pCR) rate, major pathological response (MPR) rate, TNM downstaging rate, R0 resection rate, EFS, overall survival (OS), drug safety and surgical complications.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-12
minor Completion pushed: 2026-09-01 -> 2029-12-01 2026-08-12
Trial Details
NCT Number NCT05430802
Lead Sponsor Tang-Du Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 40 participants
Start Date 2022-02-24
Primary Completion 2025-09-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11